KalVista PharmaceuticalsKALV
About: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Employees: 150
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 29
53% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 19
7% more funds holding
Funds holding: 122 [Q3] → 130 (+8) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
0.39% less ownership
Funds ownership: 112.07% [Q3] → 111.68% (-0.39%) [Q4]
17% less capital invested
Capital invested by funds: $561M [Q3] → $467M (-$93.8M) [Q4]
94% less call options, than puts
Call options by funds: $115K | Put options by funds: $1.8M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Needham Serge Belanger 39% 1-year accuracy 47 / 121 met price target | 152%upside $28 | Buy Reiterated | 26 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 33% 1-year accuracy 24 / 72 met price target | 71%upside $19 | Market Outperform Reiterated | 26 Mar 2025 |
Jones Trading Debanjana Chatterjee 17% 1-year accuracy 1 / 6 met price target | 171%upside $30 | Buy Maintained | 26 Mar 2025 |
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 102 / 357 met price target | 80%upside $20 | Buy Reiterated | 14 Mar 2025 |
JMP Securities Jonathan Wolleben 33% 1-year accuracy 24 / 72 met price target | 71%upside $19 | Market Outperform Initiated | 31 Jan 2025 |
Financial journalist opinion
Based on 6 articles about KALV published over the past 30 days









